Evaluation of the Therapeutic Efficacy of CalliSpheres Drug-eluting Microspheres in the Interventional Treatment of Primary Liver Cancer
Objective To assess the therapeutic efficacy of CalliSpheres drug-eluting microspheres in the interventional treatment of primary hepatocellular carcinoma.Methods From April 2020 to October 2022,twenty-five patients diagnosed with primary liver cancer admitted to Shenzhen Second People's Hospital underwent their initial Drug-Eluting Beads Transarterial Chemoembolization(DEB-TACE)procedure,utilizing CalliSpheres drug-eluting microspheres.Laboratory test variations,tumor activity lesion sizes before and after treatment,post-embolization adverse reactions,and medium to long-term prognosis were analyzed.Results The objective response rate(ORR)at 1,3,and 6 months post-treatment were 55.56%,61.54%,and 44.44%,respectively.The disease control rate(DCR)at 1,3,and 6 months post-treatment were 88.89%,76.92%,and 55.56%,respectively.The median overall survival(mOS)was 30.47 months[95%CI(16.02,44.91)]and the median progression-free survival(mPFS)was 19.21 months[95%CI(7.67,34.24)].Compared to pre-treatment,there was no statistically significant difference in serum α-fetoprotein(AFP)levesl at 1 and 6 months post-treatment(P>0.05),while AFP level at 3 months post-treatment decreased significantly(P<0.05).After treatment,22 patients(88%)experienced post-embolization syndrome,including abdominal pain in 18 cases(72%),nausea in 5 cases(20%),vomiting in 4 cases(16%),diarrhea in 2 cases(8%),fever in 6 cases(24%),fatigue in 5 cases(20%),headache in 1 case(4%),and bone marrow suppression in 8 cases(32%).No patients experienced severe complications such as gastrointestinal hemorrhage or liver abscess,and there were no treatment-related deaths.Conclusion CalliSpheres drug-eluting microspheres demonstrate favorable medium to long-term efficacy in the interventional treatment of hepatocellular carcinoma,and is an important treatment for patients with unresectable liver cancer patients.
万方数据
维普
